Opinion statement Strict criteria for when to stop tyrosine kinase inhibitor (TKI) therapy in
clinical practice are not easily defined without an agreement on what probability of achieving …

Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia
chromosome and oncogenic signaling by the resulting Bcr–Abl fusion protein …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …

The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …

Although imatinib is firmly established as an effective therapy for newly diagnosed patients
with chronic myeloid leukemia (CML), the field continues to advance on several fronts. In this …

In the past few years, international treatment guidelines for chronic myeloid leukaemia have
incorporated recommendations for attempting discontinuation of treatment with tyrosine …

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …

Several papers authored by international experts have proposed recommendations on the
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …

Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not
lose the major molecular response (MMR) after stopping treatment with tyrosine kinase …

After two decades of use in chronic myeloid leukaemia, the risks and benefits of established
treatment practices for BCR:: ABL1 tyrosine kinase inhibitors (TKIs) in the chronic myeloid …